| Citation: |
XIE Yanfeng, ZHU Xiaohua. Efficacy of two drug regimens in treatment of lamivudine-resistant chronic hepatitis B and their influencs on serum laminin, type Ⅳ collagen and type Ⅲ procollagen[J]. Journal of Clinical Medicine in Practice, 2022, 26(16): 113-116. DOI: 10.7619/jcmp.20220803
|
To investigate the therapeutic effect of two drug regimens on lamivudine-resistant chronic hepatitis B.
A total of 150 patients with lamivudine-resistant chronic hepatitis B admitted from September 2016 to June 2021 were selected as research objects and randomly divided into observation group and control group, with 75 cases in each group. The control group was treated with adefovir dipivoxil combined with entecavir, while the observation group was treated with tenofovir disoproxil fumarate monotherapy. The negative conversion rate of hepatitis B virus deoxyribonucleic acid (HBV-DNA) was compared between the two groups; the changes of liver function indexes and liver fibrosis indexes before and after treatment as well as the occurrence of adverse reactions were observed in the two groups.
After 12, 24 and 48 weeks of treatment, the HBV-DNA negative conversion rates of the observation group were 61.33%, 78.67% and 93.33%, respectively, which were significantly higher than 36.00%, 57.33% and 77.33% of the control group (P < 0.05). After 48 weeks of treatment, the levels of serum aspartate aminotransferase (AST), total bilirubin (TBIL) and alanine aminotransferase (ALT) as well as serum laminin (LN), type Ⅳ collagen (Ⅳ-C) and type Ⅲprocollagen (PCⅢ) levels in the two groups were significantly lower than those before treatment, and were significantly lower in the observation group than those of the control group(P < 0.05).The incidence of adverse reactions was 17.33% in the observation group and 21.33% in the control group, and there was no significant difference between the two groups (P>0.05).
Compared with adefovir dipivoxil combined with entecavir, tenofovir disoproxil fumarate monotherapy is more effective in the treatment of lamivudine-resistant chronic hepatitis B patients, which can significantly improve their liver function and liver fibrosis indexes, and has good safety and high clinical value.
| [1] |
党殿杰, 刘军英, 路振宇, 等. 拉米夫定耐药后联合阿德福韦酯治疗效果不佳的挽救治疗研究[J]. 河北医科大学学报, 2020, 41(10): 1214-1216. doi: 10.3969/j.issn.1007-3205.2020.10.021
|
| [2] |
中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1): 33-33, 52. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD201912011.htm
|
| [3] |
ZHANG Y M, ZHANG H, ZHANG J J, et al. Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate[J]. Antiviral Res, 2019, 165: 47-54. doi: 10.1016/j.antiviral.2019.03.006
|
| [4] |
黄炎清, 张红宇, 李莎莎, 等. 评估慢性乙型病毒性肝炎患者换用集采恩替卡韦的疗效与安全性[J]. 胃肠病学和肝病学杂志, 2022, 31(4): 434-437. doi: 10.3969/j.issn.1006-5709.2022.04.016
|
| [5] |
LAMPERTICO P, PAPATHEODORIDIS G V. Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe[J]. Aliment Pharmacol Ther, 2021, 53(5): 657-658.
|
| [6] |
LEE S W, CHOI J, KIM S U, et al. Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma[J]. Clin Mol Hepatol, 2021, 27(3): 402-412. doi: 10.3350/cmh.2021.0179
|
| [7] |
刘红, 徐瑞芳. 富马酸替诺福韦二吡呋酯片治疗慢性乙肝对患者肝功能及外周血IL-35表达的影响[J]. 海南医学, 2020, 31(8): 980-982. doi: 10.3969/j.issn.1003-6350.2020.08.009
|
| [8] |
白萧萧, 东冰, 高红艳, 等. 替诺福韦酯治疗慢性乙型肝炎最新研究进展[J]. 胃肠病学和肝病学杂志, 2019, 28(2): 227-231. doi: 10.3969/j.issn.1006-5709.2019.02.024
|
| [9] |
YANG D H, XIE Y J, ZHAO N F, et al. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients[J]. World J Gastroenterol, 2015, 21(9): 2746-2753. doi: 10.3748/wjg.v21.i9.2746
|
| [10] |
刘军英, 党殿杰, 路振宇, 等. 替诺福韦酯治疗拉米夫定耐药联合阿德福韦酯效果不佳的临床观察[J]. 中国医药导报, 2020, 17(15): 127-130. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202015034.htm
|
| [11] |
刘黄巧, 何清, 唐奇远, 等. 单用替诺福韦酯与恩替卡韦联合阿德福韦酯挽救治疗慢性乙型肝炎对比观察[J]. 中西医结合肝病杂志, 2017, 27(5): 284-285, 311. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXGB201705009.htm
|
| [12] |
卢婷. 替诺福韦酯治疗慢乙肝拉米夫定耐药挽救治疗应答不佳患者的疗效及安全性研究[D]. 上海: 第二军医大学, 2016.
|
| [13] |
沈伟, 陈彬, 范久波, 等. 恩替卡韦和替诺福韦酯治疗乙型肝炎肝硬化的实验室及超声指标比较[J]. 现代仪器与医疗, 2019, 25(1): 49-53. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYI201901013.htm
|
| [14] |
张玲, 郑荣, 何三军, 等. 慢性乙型肝炎患者HBV-DNA载量、肝功能指标与免疫学标志物的相关性研究[J]. 检验医学与临床, 2020, 17(22): 3348-3350. doi: 10.3969/j.issn.1672-9455.2020.22.039
|
| [15] |
张燕, 肖湘, 韩昌全, 等. 慢性乙肝患者HBV-DNA、肝功能指标与肝纤维化的关系[J]. 临床消化病杂志, 2021, 33(1): 36-40. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXH202101011.htm
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: